U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT07570862) titled 'A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis' on April 30.
Brief Summary: The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Lupus Nephritis
Systemic Lupus Erythematosus
SLE - Systemic Lupus Erythematosus
Lupus Nephritis - WHO ...